\-\ Texto\\:\\ \ \(0\)\
\-\ thyroglobulin\\ 18\\ ng\\/ml\\.\\ \\(\\ should\\ be\\ undetectable\\ \\)\ \(0\)\
\-\ total\\ or\\ near\\ total\\ thyroidectomy\\ followed\\ by\\ i\\-131\\ treatment\\ and\\ thyroid\\ hormone\\ suppression\\ with\\ continued\\ monitoring\\ of\\ thyroglobulin\\ levels\\ and\\ i\\-131\\ or\\ i\\-123\\ scans\\ usually\\ yearly\\.\\ adjunctive\\ anatomic\\ imaging\\ with\\ ultrasound\\,\\ ct\\,\\ pet\\ or\\ mri\\ scans\\ as\\ indicated\\ on\\ an\\ individual\\ basis\\.\ \(0\)\
\-\ fdg\\ pet\\ scan\\:\\ focus\\ of\\ moderately\\ intense\\ radiotracer\\ accumulation\\ in\\ r\\ supraclavicular\\ region\\.\\ increased\\ uptake\\ in\\ thymus\\.\ \(0\)\
\-\ suspected\\ metastasis\\ of\\ papillary\\ thyroid\\ cancer\ \(0\)\
\-\ metastatic\\ lesion\\,\\ reactive\\ lad\\,\\ granulomatous\\ disease\\,\\ \\ lymphoma\\,\\ retention\\ of\\ fdg\\ in\\ mediport\\.\ \(0\)\
\-\ 25\\ yo\\ female\\ patient\\ with\\ papillary\\ thyroid\\ cancer\\ s\\/p\\ thyroidectomy\\ and\\ i\\-131\\ treatment\\ with\\ recent\\ \\â\\€\\œclean\\â\\€\\\\ neck\\/chest\\ mri\\ but\\ persistently\\ high\\ thyroglobulin\\ levels\\ on\\ followup\\.\ \(0\)\
\-\ papillary\\ thyroid\\ cancer\\ is\\ the\\ most\\ common\\ type\\ of\\ thyroid\\ cancer\\ \\(70\\-90\\%\\ of\\ thyroid\\ malignancies\\)\\.\\ \\ most\\ \\(\\>80\\%\\)\\ are\\ detectedin\\ stage\\ i\\ or\\ ii\\ with\\ survival\\ curves\\ that\\ are\\ similar\\ to\\ normal\\ survival\\ curves\\.\\ \\ treatment\\ usually\\ involves\\ thyroidectomy\\ followed\\ by\\ i\\-131\\ ablation\\.\\ \\ then\\ t4\\ suppression\\ with\\ follow\\ up\\ i\\-131\\ scans\\ and\\/or\\ mri\\ scans\\.\\ \\ patient\\â\\€\\™s\\ thyroglobulin\\ levels\\ are\\ also\\ followed\\ with\\ a\\ persistently\\ high\\ level\\ \\(5\\-10\\ ng\\/ml\\)\\ suggestive\\ of\\ residual\\ thyroid\\ tissue\\/metastasis\\ requiring\\ further\\ workup\\.\\ \\ pet\\ scan\\ showing\\ a\\ lesion\\ with\\ an\\ suv\\ of\\ 3\\.5\\,\\ as\\ in\\ this\\ case\\,\\ is\\ highly\\ suggestive\\ of\\ a\\ metastatic\\ lesion\\,\\ especially\\ in\\ patient\\ with\\ persistently\\ high\\ thyroglobulin\\ levels\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thyroglobulin\\:\\ 0\\.3817791705007853\ \(0\)\
\-\ thyroid\\:\\ 0\\.3145124128306184\ \(0\)\
\-\ persistently\\:\\ 0\\.2326089435707833\ \(0\)\
\-\ thyroidectomy\\:\\ 0\\.20359137499317057\ \(0\)\
\-\ scans\\:\\ 0\\.19899218106227384\ \(0\)\
\-\ levels\\:\\ 0\\.18130148469031826\ \(0\)\
\-\ curves\\:\\ 0\\.160839215938258\ \(0\)\
\-\ papillary\\:\\ 0\\.15983452803307277\ \(0\)\
\-\ pet\\:\\ 0\\.1588486200782945\ \(0\)\
\-\ cancer\\:\\ 0\\.15232233584372024\ \(0\)\
\-\ suppression\\:\\ 0\\.13479508965600392\ \(0\)\
\-\ fdg\\:\\ 0\\.12383962153914127\ \(0\)\
\-\ followed\\:\\ 0\\.11582263529890008\ \(0\)\
\-\ survival\\:\\ 0\\.11159394951747156\ \(0\)\
\-\ with\\:\\ 0\\.1007549034000222\ \(0\)\
\-\ of\\:\\ 0\\.1006947383178715\ \(0\)\
\-\ or\\:\\ 0\\.0994455764283191\ \(0\)\
\-\ high\\:\\ 0\\.09747842959224119\ \(0\)\
\-\ total\\:\\ 0\\.09369039143424059\ \(0\)\
\-\ suggestive\\:\\ 0\\.09311268576896495\ \(0\)\
\-\ detectedin\\:\\ 0\\.09143044915260741\ \(0\)\
\-\ mri\\:\\ 0\\.08804107147495194\ \(0\)\
\-\ metastasis\\:\\ 0\\.08380568025944558\ \(0\)\
\-\ undetectable\\:\\ 0\\.08224692569248758\ \(0\)\
\-\ lesion\\:\\ 0\\.08222856319295518\ \(0\)\
\-\ treatment\\:\\ 0\\.0817021491863105\ \(0\)\
\-\ adjunctive\\:\\ 0\\.07753631452359443\ \(0\)\
\-\ mediport\\:\\ 0\\.07529985837798109\ \(0\)\
\-\ thymus\\:\\ 0\\.07434461214250845\ \(0\)\
\-\ usually\\:\\ 0\\.07198376465518154\ \(0\)\
\-\ in\\:\\ 0\\.07111267104497249\ \(0\)\
\-\ clean\\:\\ 0\\.06998163696340384\ \(0\)\
\-\ lad\\:\\ 0\\.06786379166439019\ \(0\)\
\-\ suv\\:\\ 0\\.06786379166439019\ \(0\)\
\-\ scan\\:\\ 0\\.06783900701321983\ \(0\)\
\-\ yearly\\:\\ 0\\.06739754482800196\ \(0\)\
\-\ retention\\:\\ 0\\.06695202705704519\ \(0\)\
\-\ are\\:\\ 0\\.06508250354074864\ \(0\)\
\-\ individual\\:\\ 0\\.06428901719450267\ \(0\)\
\-\ malignancies\\:\\ 0\\.06428901719450267\ \(0\)\
\-\ metastatic\\:\\ 0\\.06271194672925737\ \(0\)\
\-\ supraclavicular\\:\\ 0\\.06246169947114409\ \(0\)\
\-\ ablation\\:\\ 0\\.06246169947114409\ \(0\)\
\-\ basis\\:\\ 0\\.06115824205006288\ \(0\)\
\-\ most\\:\\ 0\\.05950806368053291\ \(0\)\
\-\ hormone\\:\\ 0\\.058214021367882125\ \(0\)\
\-\ moderately\\:\\ 0\\.05768172816686293\ \(0\)\
\-\ t4\\:\\ 0\\.057341949879996176\ \(0\)\
\-\ monitoring\\:\\ 0\\.05701331389507009\ \(0\)\
\-\ requiring\\:\\ 0\\.05701331389507009\ \(0\)\
\-\ patient\\:\\ 0\\.055785529109288294\ \(0\)\
\-\ accumulation\\:\\ 0\\.055240025949800695\ \(0\)\
\-\ intense\\:\\ 0\\.05396965703537719\ \(0\)\
\-\ workup\\:\\ 0\\.05385104618877751\ \(0\)\
\-\ anatomic\\:\\ 0\\.05305789242803219\ \(0\)\
\-\ residual\\:\\ 0\\.05202372846541892\ \(0\)\
\-\ highly\\:\\ 0\\.051176252080828766\ \(0\)\
\-\ granulomatous\\:\\ 0\\.05082143628241885\ \(0\)\
\-\ followup\\:\\ 0\\.05047875334415853\ \(0\)\
\-\ radiotracer\\:\\ 0\\.04990588316640528\ \(0\)\
\-\ involves\\:\\ 0\\.04974804526556846\ \(0\)\
\-\ showing\\:\\ 0\\.04936399446483182\ \(0\)\
\-\ reactive\\:\\ 0\\.04906700978626039\ \(0\)\
\-\ by\\:\\ 0\\.048557080656070645\ \(0\)\
\-\ focus\\:\\ 0\\.048429321277082465\ \(0\)\
\-\ and\\:\\ 0\\.04725556234404606\ \(0\)\
\-\ indicated\\:\\ 0\\.0470225897208707\ \(0\)\
\-\ continued\\:\\ 0\\.04684519571712029\ \(0\)\
\-\ suspected\\:\\ 0\\.04684519571712029\ \(0\)\
\-\ near\\:\\ 0\\.046556342884482474\ \(0\)\
\-\ as\\:\\ 0\\.04593603023699355\ \(0\)\
\-\ stage\\:\\ 0\\.04552888069380955\ \(0\)\
\-\ especially\\:\\ 0\\.045225145341725136\ \(0\)\
\-\ ii\\:\\ 0\\.045076661150912425\ \(0\)\
\-\ 80\\:\\ 0\\.04459702419955542\ \(0\)\
\-\ uptake\\:\\ 0\\.04396190227158573\ \(0\)\
\-\ an\\:\\ 0\\.04372474971296718\ \(0\)\
\-\ similar\\:\\ 0\\.043573886090159046\ \(0\)\
\-\ 18\\:\\ 0\\.04332331054972182\ \(0\)\
\-\ 25\\:\\ 0\\.040502076123293373\ \(0\)\
\-\ then\\:\\ 0\\.04047099858036706\ \(0\)\
\-\ recent\\:\\ 0\\.03871113774863681\ \(0\)\
\-\ type\\:\\ 0\\.03835315328135341\ \(0\)\
\-\ should\\:\\ 0\\.03730471610753085\ \(0\)\
\-\ further\\:\\ 0\\.03723707243413409\ \(0\)\
\-\ yo\\:\\ 0\\.03571781252791306\ \(0\)\
\-\ ultrasound\\:\\ 0\\.035264741057643795\ \(0\)\
\-\ level\\:\\ 0\\.03453518664806949\ \(0\)\
\-\ on\\:\\ 0\\.034533841154540564\ \(0\)\
\-\ region\\:\\ 0\\.03419769686436677\ \(0\)\
\-\ lymphoma\\:\\ 0\\.034049456699206\ \(0\)\
\-\ common\\:\\ 0\\.03242306358704363\ \(0\)\
\-\ is\\:\\ 0\\.03131387261363478\ \(0\)\
\-\ increased\\:\\ 0\\.030915890494061776\ \(0\)\
\-\ follow\\:\\ 0\\.0308206641286387\ \(0\)\
\-\ imaging\\:\\ 0\\.03004581254165\ \(0\)\
\-\ case\\:\\ 0\\.028722583181451718\ \(0\)\
\-\ up\\:\\ 0\\.0282808262767681\ \(0\)\
\-\ but\\:\\ 0\\.028271635538330966\ \(0\)\
\-\ female\\:\\ 0\\.027588119333562994\ \(0\)\
\-\ also\\:\\ 0\\.026892062869932516\ \(0\)\
\-\ that\\:\\ 0\\.024810497115134826\ \(0\)\
\-\ disease\\:\\ 0\\.023998767927147103\ \(0\)\
\-\ normal\\:\\ 0\\.023342937805121103\ \(0\)\
\-\ be\\:\\ 0\\.02319238838848861\ \(0\)\
\-\ ct\\:\\ 0\\.0217659111708931\ \(0\)\
\-\ this\\:\\ 0\\.019645323362746634\ \(0\)\
\-\ to\\:\\ 0\\.014292883753226298\ \(0\)\
\-\ the\\:\\ 0\\.011407882460782365\ \(0\)\
